TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3568582

Group type: EXPERIMENTAL
Intervention: beta-blockade (2 X 80 mg oral propranolol per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 16
Study: 29979799

Group type: EXPERIMENTAL
Intervention: Continuous Cryotherapy (CC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ice (ICE)
Number of subjects: 40
Study: 27632270

Group type: EXPERIMENTAL
Intervention: Nonsplinted implants
Number of subjects: 18

Group type: COMPARATOR
Intervention: Splinted implants
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All implants
Number of subjects: 18
Study: 24935020

Group type: EXPERIMENTAL
Intervention: Beta-blocker (BB) titration
Number of subjects: 728

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 728
Study: 22677046

Group type: EXPERIMENTAL
Intervention: Dual SLIT with TG and DM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20435964

Group type: EXPERIMENTAL
Intervention: Early intervention service
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 144
Study: 18618738

Group type: EXPERIMENTAL
Intervention: Fulvestrant (500 mg on day 0, then 250 mg on day 14, day 28, and monthly thereafter)
Number of subjects: 20
Study: 15984601

Group type: EXPERIMENTAL
Intervention: Budesonide via Clickhaler
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Budesonide via Turbuhaler
Number of subjects: 27

Group type: COMPARATOR
Intervention: Budesonide (both devices)
Number of subjects: 27
Study: 12888225

Group type: EXPERIMENTAL
Intervention: CC‐SIT
Number of subjects: 0

Group type: COMPARATOR
Intervention: UPSIT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WMS‐III Logical Memory I
Number of subjects: 0
Study: 10420346

Group type: EXPERIMENTAL
Intervention: Randomised Controlled Trials (RCTs)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Medline interrogation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Newly identified trials
Number of subjects: 10
Study: 7550956

Group type: EXPERIMENTAL
Intervention: Dynamic orthopaedic brace after 10-day plaster immobilization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Weight-bearing short-leg plaster cast for 25 days
Number of subjects: 20
Study: 2046054

Group type: EXPERIMENTAL
Intervention: Stress management intervention training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Type A management
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed Type A management intervention
Number of subjects: 30
Study: 7453623

Group type: EXPERIMENTAL
Intervention: Influenza vaccine A/USSR/90/77
Number of subjects: 51

Group type: COMPARATOR
Intervention: Influenza vaccine A/Brazil/11/78
Number of subjects: 51
Study: 31171039

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Number of subjects: 436

Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 436
Study: 28627914

Group type: EXPERIMENTAL
Intervention: AWARE group motivational interviewing intervention (4 sessions)
Number of subjects: 100
Study: 26535968

Group type: COMPARATOR
Intervention: 10, 20, 30, or 40 mg hydrocodone-ER (single dose)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 10, 20, 30, or 40 mg hydrocodone-ER (twice-daily for 7 days)
Number of subjects: 152

Group type: COMPARATOR
Intervention: 10 mg hydrocodone/325 mg acetaminophen IR
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: hydrocodone-ER (single and multiple doses)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: hydrocodone-ER
Number of subjects: 152
Study: 21594682

Group type: EXPERIMENTAL
Intervention: Early and personalized congestion-guided ambulatory program (Group A) with close follow-up visits at 10 days, 20 days, and months 1, 2, 3 after discharge.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional ambulatory follow-up (Group B) only at months 1, 2, 3 after discharge.
Number of subjects: 43
Study: 21929716

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (Blink Intensive, Abbot Medical Optics Inc, CA, USA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypromellose (Artific, Farma-Lepori SA, Barcelona, Spain)
Number of subjects: 20
Study: 20129552

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1294
Study: 17414929

Group type: EXPERIMENTAL
Intervention: FTC/TDF (200/300 mg once daily) for 7 days followed by GS-9137/r (50/100 mg once daily) and GS-9137/r plus FTC/TDF in a crossover fashion for 10 days.
Number of subjects: 26

Group type: COMPARATOR
Intervention: GS-9137/r (50/100 mg once daily) alone.
Number of subjects: 26
Study: 15384797

Group type: EXPERIMENTAL
Intervention: Once-weekly mupirocin application (n = 18; men/women: 10/8; age: 55.3 ± 1.8 years)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Thrice-weekly mupirocin application (n = 18; men/women: 11/7; age: 55.0 ± 2.3 years)
Number of subjects: 36
Study: 14671238

Group type: EXPERIMENTAL
Intervention: Community-based multidisciplinary stroke team (CST) approach
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual inpatient rehabilitation and follow-up care
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Community group (CST)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Caregiver satisfaction
Number of subjects: 113
Study: 10511404

Group type: EXPERIMENTAL
Intervention: Ceftazidime i.v. (1 g tid) + netilmicin i.v. (2 mg/kg bodyweight tid)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Cefotaxime i.v. (2 g tid) + netilmicin i.v. (2 mg/kg bodyweight tid)
Number of subjects: 186
Study: 7792725

Group type: EXPERIMENTAL
Intervention: Inaccurate diagnostic tests (fibrinogen scanning)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive screening tests supplemented by venography
Number of subjects: 0
Study: 2037703

Group type: EXPERIMENTAL
Intervention: Guanfacine, 1 mg every night
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Methyldopa, 250 mg tid
Number of subjects: 112

Group type: COMPARATOR
Intervention: Guanfacine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 112

Group type: COMPARATOR
Intervention: Guanfacine and Methyldopa
Number of subjects: 112
Study: 6454485

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (Provera)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nafoxidine
Number of subjects: 70
Study: 31943216

Group type: EXPERIMENTAL
Intervention: Generalized periodontitis (GP) group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 20
Study: 31287757

Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (EVT) for M2 occlusions
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Endovascular Treatment (EVT) for M1 occlusions
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (EVT) for dominant M2 occlusions
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (EVT) for nondominant M2 occlusions
Number of subjects: 1003
Study: 29567116

Group type: COMPARATOR
Intervention: GFF MDI 144/38.4, GFF MDI 18/9.6, GP MDI 144 μg
Number of subjects: 307

Group type: COMPARATOR
Intervention: GFF MDI 36/9.6, GP MDI 36, FF MDI 9.6 μg
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: GFF MDI 144/38.4 μg
Number of subjects: 307
Study: 26864369

Group type: EXPERIMENTAL
Intervention: Egg intake (1 additional egg (55 g)/d)
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Cholesterol intake (100 mg/d higher)
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Egg or cholesterol intakes
Number of subjects: 1032
Study: 25146716

Group type: EXPERIMENTAL
Intervention: Commercial dual-ring wound protector (the Alexis Wound Protector)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No wound protector (current standard of care)
Number of subjects: 0
Study: 22730491

Group type: EXPERIMENTAL
Intervention: Authoritative Parenting Model (APM)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control Group 1 (conventional dental education and behavior modification)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control Group 2 (conventional behavior modification)
Number of subjects: 247

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 247
Study: 19186107

Group type: EXPERIMENTAL
Intervention: Relaxing music (MusiCure)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 240
Study: 17937567

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (q.d.) or 60 mg twice daily (b.i.d.)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study: 15834296

Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 183
Study: 11870100

Group type: EXPERIMENTAL
Intervention: Laparoscopic salpingectomy for hydrosalpinges prior to IVF
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no surgical intervention)
Number of subjects: 3
Study: 9425914

Group type: EXPERIMENTAL
Intervention: Ornipressin and albumin for 3 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ornipressin and albumin for 15 days
Number of subjects: 16
Study: 7624264

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice/day
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at bedtime
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 31053945

Group type: EXPERIMENTAL
Intervention: PF-05280014
Number of subjects: 702

Group type: COMPARATOR
Intervention: trastuzumab-EU
Number of subjects: 702
Study: 29444712

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study: 26655097

Group type: EXPERIMENTAL
Intervention: Resorbable collagen membrane (CM group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonresorbable high-density polytetrafluoroethylene membrane (PTFE group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 24849545

Group type: EXPERIMENTAL
Intervention: IMC‐A12 + mitotane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mitotane as a single agent
Number of subjects: 20
Study: 22333737

Group type: EXPERIMENTAL
Intervention: VEG (vegetarian group avoiding meat, fish, and poultry)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: FISH (group consuming fish 3-4 times weekly but avoiding meat and poultry)
Number of subjects: 39

Group type: COMPARATOR
Intervention: OMN (control group consuming meat, fish, and poultry daily)
Number of subjects: 39
Study: 19268878

Group type: EXPERIMENTAL
Intervention: Reminders sent to both physician and patient
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Reminders sent to patient only
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Reminders sent to physician only
Number of subjects: 223

Group type: COMPARATOR
Intervention: No reminders sent (control group)
Number of subjects: 223
Study: 17299076

Group type: EXPERIMENTAL
Intervention: Total thyroid ablation (TTA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Near-total thyroidectomy (TX)
Number of subjects: 60
Study: 15231507

Group type: EXPERIMENTAL
Intervention: Intervention based on absolute risk reduction model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention based on relative risk reduction model
Number of subjects: 0
Study: 11688936

Group type: EXPERIMENTAL
Intervention: Oral protein energy supplements (120 mL sip feed, 3 times daily, 540 kcal, 22.5 g protein per day)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Oral protein energy supplements
Number of subjects: 381

Group type: COMPARATOR
Intervention: Overall mortality
Number of subjects: 381
Study: 9387052

Group type: EXPERIMENTAL
Intervention: Helical CT pitch 1.0
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Helical CT pitch 1.5
Number of subjects: 75

Group type: COMPARATOR
Intervention: Helical CT pitch 2.0
Number of subjects: 75
Study: 8192610

Group type: EXPERIMENTAL
Intervention: First week of abstinence
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Second week of abstinence
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Fourth week of abstinence
Number of subjects: 179
Study: 3580240

Group type: EXPERIMENTAL
Intervention: Stretch exercises performed approximately 1 hour before operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suxamethonium without pretreatment (Control)
Number of subjects: 0
Study: 28770628

Group type: EXPERIMENTAL
Intervention: Knee brace without a patellar hole
Number of subjects: 108

Group type: COMPARATOR
Intervention: Knee brace with a patellar hole
Number of subjects: 108
Study: 26447067

Group type: EXPERIMENTAL
Intervention: Specialized palliative care (PC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 26241537

Group type: EXPERIMENTAL
Intervention: Mesalazine enema 4 g/day (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 3 mg/60 ml every day (group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of mesalazine and BDP (group C)
Number of subjects: 120
Study: 23950156

Group type: EXPERIMENTAL
Intervention: Travoprost plus timolol fixed combination (TTFC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Latanoprost plus timolol fixed combination (LTFC)
Number of subjects: 59
Study: 20582993

Group type: EXPERIMENTAL
Intervention: L-dopa/carbidopa/entacapone (LCE)
Number of subjects: 747

Group type: COMPARATOR
Intervention: L-dopa/carbidopa (LC)
Number of subjects: 747
Study: 17882232

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 14618372

Group type: EXPERIMENTAL
Intervention: True mud compresses
Number of subjects: 45

Group type: COMPARATOR
Intervention: Attenuated mud compresses
Number of subjects: 45
Study: 12933409

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Intermittent opiate regimen (IOR)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 3
Study: 10097930

Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5-4 mg t.i.d.)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Glyburide (1.75-10.5 mg daily)
Number of subjects: 424
Study: 8762729

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acute GH
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3 days GH
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3 weeks GH
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All treatment periods
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 15
Study: 1867965

Group type: EXPERIMENTAL
Intervention: Disopyramide (150 mg racemic drug administered intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine (400 mg twice daily orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disopyramide (both enantiomers)
Number of subjects: 0
Study: 6813952

Group type: EXPERIMENTAL
Intervention: Glucose group (carbohydrate alone)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Amino acid group (excess amino acids, less carbohydrates)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lipid group (carbohydrates and fats)
Number of subjects: 37
Study: 30719645

Group type: EXPERIMENTAL
Intervention: Polypharmacy (average number of non-statin medications: 11.6, SD 5.0)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Polypharmacy (adjusted for symptom burden)
Number of subjects: 372
Study: 29382400

Group type: EXPERIMENTAL
Intervention: Ethanol (61% w/v) plus chlorhexidine gluconate (1.0% solution)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ethanol only (70% v/v)
Number of subjects: 51
Study: 26752119

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24580390

Group type: EXPERIMENTAL
Intervention: 7.5 µg/kg morphine with 0.125% levobupivacaine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 10 µg/kg morphine with 0.125% levobupivacaine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 15 µg/kg morphine with 0.125% levobupivacaine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study: 22503387

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic receptor blockade during reconsolidation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 20714138

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-Carbohydrate (HC) meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-Fat (HF) meal
Number of subjects: 15
Study: 17039380

Group type: EXPERIMENTAL
Intervention: Laying on of hands by a healer
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laying on of hands by an actor
Number of subjects: 80
Study: 15189383

Group type: EXPERIMENTAL
Intervention: Computerized evidence-based guideline
Number of subjects: 0
Study: 11488317

Group type: EXPERIMENTAL
Intervention: 200 microg inhaled salbutamol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 500 microg inhaled terbutaline
Number of subjects: 20
Study: 9754108

Group type: EXPERIMENTAL
Intervention: Unenhanced helical CT (UHCT) interpretation by attending radiologists
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Unenhanced helical CT (UHCT) interpretation by radiology attending physicians and resident
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Unenhanced helical CT (UHCT) interpretation by urologist
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Overall accuracy of UHCT interpretation
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Percentage of UHCT scans correctly interpreted as positive
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Percentage of UHCT scans correctly interpreted as negative
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Indeterminate cases interpretation
Number of subjects: 103
Study: 7929871

Group type: EXPERIMENTAL
Intervention: Zopolrestat 800 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopolrestat 1200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopolrestat (dose range 50 to 1200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopolrestat
Number of subjects: 0
Study: 3247253

Group type: EXPERIMENTAL
Intervention: DGAVP (desglycinamide‐arginine‐vasopressin)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30096636

Group type: EXPERIMENTAL
Intervention: Pictorial warnings on cigarette packs (Trial 1)
Number of subjects: 2868

Group type: EXPERIMENTAL
Intervention: Messages about toxic chemicals in cigarette smoke (Trial 2)
Number of subjects: 2868

Group type: COMPARATOR
Intervention: Text-only warnings on cigarette packs (Trial 1)
Number of subjects: 2868

Group type: COMPARATOR
Intervention: Messages about not littering cigarette butts (Trial 2)
Number of subjects: 2868
Study: 26683485

Group type: EXPERIMENTAL
Intervention: Paediatric chemotherapy protocol (UKALL2003)
Number of subjects: 229
Study: 24885921

Group type: EXPERIMENTAL
Intervention: Variable lung protective ventilation (VV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional lung protective ventilation (CV)
Number of subjects: 50
Study: 22269899

Group type: EXPERIMENTAL
Intervention: Multichamber bag (MCB)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Compounded PN made with olive oil (COM1)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Compounded PN made with MCT/LCT (COM2)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Compounded PN (COM1 + COM2)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Secondary outcomes
Number of subjects: 406
Study: 20592655

Group type: EXPERIMENTAL
Intervention: 3-month exercise program (experimental group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 94
Study: 18403448

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (goal: >= 45 min/day, 5 days/week)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Stretching control (1 day/week stretching classes)
Number of subjects: 115
Study: 15813712

Group type: EXPERIMENTAL
Intervention: MD-DP-SOS system (computer-aided disease prediction model)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard method)
Number of subjects: 0
Study: 12067167

Group type: EXPERIMENTAL
Intervention: Heparin‐coated oxygenator with a centrifugal pump and low‐dose heparinization (100 IU/kg bolus, ACT of 180‐400 s)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Regular uncoated bypass equipment with a roller pump and full‐dose heparinization (300 IU/kg bolus, ACT > 400 s)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Heparin‐coated perfusion circuits with full‐dose heparinization
Number of subjects: 90
Study: 10800057

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) administered 7-15 hours after busulphan (Bu)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cyclophosphamide (CP) administered 24-50 hours after busulphan (Bu)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cyclophosphamide (CP) administered after TBI
Number of subjects: 36
Study: 8992907

Group type: EXPERIMENTAL
Intervention: General endotracheal anaesthesia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Local anaesthesia with sedation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All anaesthetic techniques
Number of subjects: 19
Study: 1677545

Group type: EXPERIMENTAL
Intervention: Vecuronium infusion during isoflurane-narcotic-nitrous oxide anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium infusion during halothane-narcotic-nitrous oxide anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium infusion during narcotic-nitrous oxide anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recovery index after termination of vecuronium infusion
Number of subjects: 0